PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 5, 2026Journal of Clinical Oncology9 citations

Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Adenocarcinoma

Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study.

View Full Paper
Ask AI
Bookmark
Share

Authors

BWBrian M. WolpinZWZev A. WainbergAHAndrew Hendifar

Discussion

Loading...

Member takes

Overview

Randomized trial compares daraxonrasib's efficacy in improving survival in 2L mPDAC, suggesting a potential new standard of care.

Key Points

  • This research aims to evaluate the efficacy of daraxonrasib, a RAS inhibitor, compared to standard chemotherapy in patients with metastatic pancreatic adenocarcinoma.
  • Phase 3 randomized clinical trial (NCT06625320) with patients having 2L metastatic pancreatic adenocarcinoma.
  • Patients randomized 1:1 to receive either daraxonrasib 300 mg once daily or investigator's choice of standard chemotherapy.
  • Endpoints included overall survival and progression-free survival assessed by blinded independent central review (BICR) in RAS G12 population.
  • Median overall survival was 13.2 months for daraxonrasib vs 6.6 months for chemotherapy (HR 0.40, 95% CI 0.30-0.54, p<0.0001).
  • Median progression-free survival was 7.3 months for daraxonrasib vs 3.5 months for chemotherapy (HR 0.45, 95% CI 0.34-0.59, p<0.0001).
  • Daraxonrasib had a lower adverse event rate with 43.6% experiencing grade ≥3 treatment-related adverse effects compared to 57.5% for chemotherapy.

Cite This Study

Wolpin et al. (2026) studied this question.

synapsesocial.com/papers/6a2267a3763171746d5463f9https://doi.org/10.1200/jco.2026.44.17_suppl.lba5
View Full Paper
Ask AI
Bookmark
Share